 TCTMD | Korean Registry Confirms Edge of Everolimus- Over Zotarolimus-Eluting Stents TCTMD Among next-generation drug-eluting stents (DES), those that elute everolimus are more effective at reducing stent thrombosis and target lesion revascularization (TLR) at 1 year than those that release zotarolimus, according to a Korean registry ... |
